{"gene":"ZBTB1","run_date":"2026-04-28T23:00:23","timeline":{"discoveries":[{"year":2014,"finding":"ZBTB1, via its UBZ4 domain, acts as a critical upstream regulator of translesion DNA synthesis (TLS) by associating with KAP-1 and promoting phospho-KAP-1 localization to UV damage sites, which relaxes chromatin and enhances RAD18 recruitment, thereby enabling PCNA monoubiquitination and TLS polymerase recruitment.","method":"Co-immunoprecipitation, domain mutagenesis (UBZ4), siRNA depletion, immunofluorescence at UV damage sites, UV survival assays","journal":"Molecular cell","confidence":"High","confidence_rationale":"Tier 2 — reciprocal Co-IP, domain mutagenesis, multiple orthogonal functional readouts in a single study","pmids":["24657165"],"is_preprint":false},{"year":2011,"finding":"ZBTB1 is localized to the nucleus (dot-like structures) and functions as a transcriptional repressor of CRE-mediated transcription, with both the BTB/POZ domain and zinc finger motifs required for suppression of cAMP response element activity.","method":"Subcellular localization by fluorescence microscopy, luciferase transcriptional activity assays, domain deletion analysis in COS7 cells","journal":"Molecular and cellular biochemistry","confidence":"Medium","confidence_rationale":"Tier 2 — direct localization and functional transcription assays; single lab, moderate methods","pmids":["21706167"],"is_preprint":false},{"year":2011,"finding":"ZBTB1 is a cell-intrinsic determinant of T cell development and lymphopoiesis; a point mutation in Zbtb1 identified by positional cloning and confirmed by retroviral transduction/somatic reversion causes complete T cell deficiency and partial impairment of other lymphoid lineages.","method":"ENU mutagenesis screen, positional cloning, retroviral transduction rescue, somatic reversion analysis in mouse","journal":"The Journal of experimental medicine","confidence":"High","confidence_rationale":"Tier 2 — genetic epistasis by multiple complementary approaches (cloning, rescue, reversion) in vivo","pmids":["22201126"],"is_preprint":false},{"year":2020,"finding":"ZBTB1 directly binds the ASNS (asparagine synthetase) promoter and promotes ASNS transcription, making it uniquely essential for asparagine synthesis under asparagine deprivation; ZBTB1 knockout cells cannot synthesize asparagine and are sensitized to L-asparaginase.","method":"Functional genomics/CRISPR screens, ChIP (ZBTB1 at ASNS promoter), knockout cell lines, L-asparaginase survival assays","journal":"Cell metabolism","confidence":"High","confidence_rationale":"Tier 2 — genome-wide screen, ChIP validation, KO with specific metabolic phenotype; replicated in multiple leukemia cell contexts","pmids":["32268116"],"is_preprint":false},{"year":2016,"finding":"Zbtb1 maintains genome integrity in lymphoid progenitors by enabling efficient S-phase checkpoint activation; Zbtb1-mutant progenitors display increased replication stress-associated DNA damage and p53-mediated apoptosis, which can be rescued by Bcl2 overexpression or p53 deficiency—though a Zbtb1-specific block remains at the DN3 stage independent of apoptosis.","method":"Bone marrow chimeras with ScanT mutant mice, γH2AX foci quantification, competitive reconstitution, Bcl2 transgene rescue, p53 knockout epistasis","journal":"Journal of immunology","confidence":"High","confidence_rationale":"Tier 2 — genetic epistasis with multiple rescue experiments and orthogonal phenotypic readouts","pmids":["27402700"],"is_preprint":false},{"year":2016,"finding":"Zbtb1 expression in lymphoid-primed multipotent progenitors (LMPPs) prevents default myeloid differentiation; Zbtb1-deficient LMPPs upregulate a myeloid gene signature and generate myeloid cells even under lymphoid-inducing conditions without myeloid cytokines, and this lineage bias is independent of p53/Bcl2.","method":"In vitro differentiation assays, gene expression profiling, conditional Zbtb1 deficiency in LMPPs, Bcl2/p53 epistasis","journal":"Oncotarget","confidence":"Medium","confidence_rationale":"Tier 2 — clean KO with defined lineage phenotype and epistasis controls; single lab","pmids":["27542215"],"is_preprint":false},{"year":2017,"finding":"Zbtb1 is cell-intrinsically required for development of NKp46+ RORγt+ ILC3s; Zbtb1-deficient progenitors fail to generate NKp46+ ILC3s in bone marrow chimeras and co-cultures with OP9-DL1 stroma, and fail to upregulate T-bet and acquire IFN-γ production.","method":"Bone marrow chimeras, co-culture with OP9-DL1 stroma, flow cytometry, cytokine production assays in Zbtb1-deficient mice","journal":"Oncotarget","confidence":"Medium","confidence_rationale":"Tier 2 — cell-intrinsic rescue experiment in chimeras plus in vitro co-culture; single lab","pmids":["28915559"],"is_preprint":false},{"year":2020,"finding":"ZBTB1 occupies the ERα-binding site of the HER2 intron and suppresses tamoxifen-induced HER2 transcription in tamoxifen-resistant breast cancer cells; miR-23b-3p directly targets ZBTB1 to relieve this repression, thereby increasing HER2 expression and aerobic glycolysis.","method":"ChIP for ZBTB1 at HER2 regulatory sequences, luciferase reporter for miR-23b-3p targeting, ZBTB1 overexpression/knockdown, in vivo xenograft","journal":"The Journal of biological chemistry","confidence":"Medium","confidence_rationale":"Tier 2 — ChIP plus reporter assay plus in vivo validation; single lab","pmids":["32690611"],"is_preprint":false},{"year":2022,"finding":"Zbtb1 interacts with Lmo2 (identified by two-step affinity purification/LC-MS/MS) and forms a complex with Cbfa2t3; the Lmo2/Zbtb1/Cbfa2t3 complex co-binds the Tcf7 upstream enhancer (shown by ChIP-seq) in lymphoid progenitors, maintaining Tcf7 expression and Notch-mediated T-lineage differentiation capacity.","method":"Two-step affinity purification with LC-MS/MS, CRISPR/Cas9 acute disruption, ChIP-seq, transcriptome analysis, Tcf7 retroviral rescue","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 1–2 — MS-based interactome, ChIP-seq co-binding, CRISPR KO with specific transcriptional phenotype, and rescue experiment","pmids":["36126774"],"is_preprint":false},{"year":2023,"finding":"ZBTB1 interacts with EYA3 (identified by mass spectrometry proteomics) and, as a major transcription factor partner, dictates gene expression during myoblast differentiation; EYA3 isoforms differentially regulate this transcriptional partnership.","method":"Mass spectrometry-based proteomics, genome-wide transcriptomics (RNA-seq), co-IP/pulldown","journal":"iScience","confidence":"Medium","confidence_rationale":"Tier 2 — MS interactome with transcriptomic follow-up; single lab, moderate functional characterization of the specific ZBTB1–EYA3 interaction","pmids":["38026174"],"is_preprint":false},{"year":2024,"finding":"Zbtb1 is a lymphoid-specifying transcription factor active in Kit-lo HSCs; deletion of Zbtb1 in Kit-lo HSCs diminishes their T-cell potential, while re-expression in megakaryocytic-biased Kit-hi HSCs rescues T-cell potential in vitro and in vivo.","method":"Chromatin profiling (ATAC-seq), CRISPR deletion, retroviral re-expression, in vitro and in vivo T-cell potential assays in allo-HCT mouse model","journal":"bioRxiv","confidence":"Medium","confidence_rationale":"Tier 2 — chromatin profiling plus gain- and loss-of-function in vivo; preprint, not yet peer-reviewed","pmids":["bio_10.1101_2024.06.06.597775"],"is_preprint":true}],"current_model":"ZBTB1 is a nuclear transcriptional repressor (via its BTB/POZ and C2H2 zinc finger domains) that operates in at least three distinct mechanistic contexts: (1) it binds the ASNS promoter to drive asparagine synthetase transcription under amino acid stress; (2) its UBZ4 domain recruits phospho-KAP-1 to UV-damaged chromatin, enabling RAD18 access, PCNA monoubiquitination, and translesion synthesis; and (3) as part of a Lmo2/Zbtb1/Cbfa2t3 complex, it co-occupies the Tcf7 enhancer to maintain Notch-responsive T-lineage differentiation capacity in lymphoid progenitors."},"narrative":{"teleology":[{"year":2011,"claim":"Establishing that ZBTB1 is a nuclear transcriptional repressor revealed its basic molecular identity — it localizes to nuclear dot-like structures and represses CRE-mediated transcription through both its BTB/POZ domain and zinc finger motifs.","evidence":"Fluorescence microscopy and luciferase reporter assays with domain deletions in COS7 cells","pmids":["21706167"],"confidence":"Medium","gaps":["Endogenous genomic targets were not identified","Mechanism of repression (co-repressor recruitment, histone modification) unknown","No assessment in primary cell types"]},{"year":2011,"claim":"Positional cloning of a T-cell-deficient ENU mutant mouse and retroviral rescue demonstrated that ZBTB1 is a cell-intrinsic determinant of T lymphopoiesis, establishing its first in vivo function.","evidence":"ENU mutagenesis screen, positional cloning, retroviral transduction rescue, somatic reversion in mouse","pmids":["22201126"],"confidence":"High","gaps":["Direct transcriptional targets in T-cell progenitors were not identified","Mechanism by which the point mutation disrupts ZBTB1 function was unclear"]},{"year":2014,"claim":"Discovery of a non-transcriptional role resolved how ZBTB1 contributes to genome integrity: its UBZ4 domain recruits phospho-KAP-1 to UV-damaged chromatin, relaxing chromatin to allow RAD18-dependent PCNA monoubiquitination and translesion synthesis.","evidence":"Reciprocal Co-IP, UBZ4 domain mutagenesis, siRNA depletion, immunofluorescence at UV damage sites, UV survival assays","pmids":["24657165"],"confidence":"High","gaps":["Whether the UBZ4 domain directly binds ubiquitin or a ubiquitinated substrate was not resolved","Relevance of this pathway to the lymphoid phenotype was not tested"]},{"year":2016,"claim":"Epistasis experiments clarified that Zbtb1 protects lymphoid progenitors from replication-stress-induced DNA damage and p53-dependent apoptosis, yet a p53-independent block at DN3 revealed an additional lineage-specification role beyond survival.","evidence":"γH2AX quantification, Bcl2 transgene rescue, p53 knockout epistasis in bone marrow chimeras of ScanT mutant mice","pmids":["27402700"],"confidence":"High","gaps":["Identity of the replication-stress target(s) was not determined","Molecular basis of the p53-independent DN3 block remained open"]},{"year":2016,"claim":"Demonstrating that Zbtb1-deficient LMPPs default to myeloid fate even under lymphoid-inducing conditions established ZBTB1 as a gatekeeper of lymphoid versus myeloid lineage choice upstream of survival control.","evidence":"In vitro differentiation assays with gene expression profiling and Bcl2/p53 epistasis in Zbtb1-deficient LMPPs","pmids":["27542215"],"confidence":"Medium","gaps":["Direct myeloid gene targets repressed by ZBTB1 were not identified","Single-lab finding without independent replication"]},{"year":2017,"claim":"Extension of the lymphoid requirement to innate lymphoid cells showed that Zbtb1 is cell-intrinsically required for NKp46+ RORγt+ ILC3 development and T-bet-dependent IFN-γ acquisition.","evidence":"Bone marrow chimeras and OP9-DL1 co-culture with flow cytometry in Zbtb1-deficient mice","pmids":["28915559"],"confidence":"Medium","gaps":["Direct transcriptional targets in ILC3 progenitors not mapped","Single-lab study"]},{"year":2020,"claim":"Genome-wide CRISPR screens and ChIP revealed that ZBTB1 directly binds the ASNS promoter to drive asparagine synthetase transcription, establishing a metabolic vulnerability: ZBTB1-null leukemia cells cannot synthesize asparagine and are hypersensitive to L-asparaginase.","evidence":"CRISPR screens in multiple leukemia cell lines, ChIP at ASNS promoter, knockout metabolic and survival assays","pmids":["32268116"],"confidence":"High","gaps":["Whether ZBTB1 acts as an activator or relieves a repressor at ASNS was mechanistically unresolved","Relevance to non-leukemic contexts not established"]},{"year":2020,"claim":"ChIP showed ZBTB1 occupies the ERα-binding site in the HER2 intron and suppresses HER2 transcription, linking ZBTB1 to tamoxifen resistance in breast cancer through a miR-23b-3p/ZBTB1/HER2 regulatory axis.","evidence":"ChIP at HER2 regulatory sequences, luciferase reporter, ZBTB1 overexpression/knockdown, xenograft model","pmids":["32690611"],"confidence":"Medium","gaps":["Mechanism of ZBTB1-mediated repression at HER2 locus not defined","Single-lab study"]},{"year":2022,"claim":"Identification of a LMO2/ZBTB1/CBFA2T3 complex co-occupying the Tcf7 enhancer provided the first molecular mechanism for ZBTB1's T-lineage specification role — maintaining Tcf7 expression and Notch responsiveness in lymphoid progenitors.","evidence":"Two-step affinity purification/LC-MS/MS, ChIP-seq co-binding, CRISPR KO, retroviral Tcf7 rescue","pmids":["36126774"],"confidence":"High","gaps":["Whether the complex acts as an activator or prevents silencing was not distinguished","Structural basis of the ternary complex unknown"]},{"year":2023,"claim":"Proteomic identification of ZBTB1–EYA3 interaction expanded ZBTB1's partnership repertoire to myoblast differentiation, showing it partners with the phosphatase/transactivator EYA3 to regulate differentiation-associated gene expression.","evidence":"Mass spectrometry-based proteomics, RNA-seq, co-IP in myoblast differentiation system","pmids":["38026174"],"confidence":"Medium","gaps":["Direct genomic co-occupancy of ZBTB1 and EYA3 not demonstrated","Functional significance of EYA3 isoform-specific effects on ZBTB1 activity not resolved"]},{"year":null,"claim":"How ZBTB1's transcriptional and chromatin-remodeling functions are coordinated across its distinct biological roles — T-lineage commitment, metabolic stress response, DNA damage tolerance, and potentially myogenesis — remains an open question, as does whether its activating versus repressing activities are context-determined by distinct partner complexes.","evidence":"","pmids":[],"confidence":"Medium","gaps":["No structural model of full-length ZBTB1 or its complexes exists","Genome-wide binding profile in primary hematopoietic progenitors is incomplete","Relationship between UBZ4-mediated DNA damage function and transcriptional roles is untested"]}],"mechanism_profile":{"molecular_activity":[{"term_id":"GO:0140110","term_label":"transcription regulator activity","supporting_discovery_ids":[1,3,7,8]},{"term_id":"GO:0003677","term_label":"DNA binding","supporting_discovery_ids":[3,7,8]}],"localization":[{"term_id":"GO:0005634","term_label":"nucleus","supporting_discovery_ids":[1]}],"pathway":[{"term_id":"R-HSA-73894","term_label":"DNA Repair","supporting_discovery_ids":[0,4]},{"term_id":"R-HSA-74160","term_label":"Gene expression (Transcription)","supporting_discovery_ids":[1,3,7,8]},{"term_id":"R-HSA-1266738","term_label":"Developmental Biology","supporting_discovery_ids":[2,5,6,8]},{"term_id":"R-HSA-168256","term_label":"Immune System","supporting_discovery_ids":[2,5,6]}],"complexes":["LMO2/ZBTB1/CBFA2T3"],"partners":["KAP1","LMO2","CBFA2T3","RAD18","EYA3"],"other_free_text":[]},"mechanistic_narrative":"ZBTB1 is a nuclear BTB/POZ- and C2H2-zinc-finger-containing transcription factor that operates at the intersection of lineage commitment, metabolic adaptation, and genome maintenance. In hematopoietic progenitors, ZBTB1 forms a complex with LMO2 and CBFA2T3 to co-occupy the Tcf7 enhancer, sustaining Notch-responsive T-lineage differentiation capacity; its loss causes complete T-cell deficiency, impaired ILC3 development, and default myeloid differentiation of lymphoid-primed progenitors [PMID:22201126, PMID:36126774, PMID:28915559, PMID:27542215]. ZBTB1 directly binds the ASNS promoter to drive asparagine synthetase transcription under amino acid stress, rendering ZBTB1-null cells unable to synthesize asparagine and hypersensitive to L-asparaginase [PMID:32268116]. Independent of its transcriptional roles, ZBTB1 uses a UBZ4 domain to recruit phospho-KAP-1 to UV-damaged chromatin, relaxing local chromatin structure so that RAD18 can access PCNA for monoubiquitination and translesion synthesis [PMID:24657165]."},"prefetch_data":{"uniprot":{"accession":"Q9Y2K1","full_name":"Zinc finger and BTB domain-containing protein 1","aliases":[],"length_aa":713,"mass_kda":82.0,"function":"Acts as a transcriptional repressor (PubMed:20797634). Represses cAMP-responsive element (CRE)-mediated transcriptional activation (PubMed:21706167). In addition, has a role in translesion DNA synthesis. Requires for UV-inducible RAD18 loading, PCNA monoubiquitination, POLH recruitment to replication factories and efficient translesion DNA synthesis (PubMed:24657165). Plays a key role in the transcriptional regulation of T lymphocyte development (By similarity)","subcellular_location":"Nucleus; Nucleus, nucleoplasm","url":"https://www.uniprot.org/uniprotkb/Q9Y2K1/entry"},"depmap":{"release":"DepMap","has_data":true,"is_common_essential":false,"resolved_as":"","url":"https://depmap.org/portal/gene/ZBTB1","classification":"Not Classified","n_dependent_lines":15,"n_total_lines":1208,"dependency_fraction":0.012417218543046357},"opencell":{"profiled":false,"resolved_as":"","ensg_id":"","cell_line_id":"","localizations":[],"interactors":[],"url":"https://opencell.sf.czbiohub.org/search/ZBTB1","total_profiled":1310},"omim":[{"mim_id":"616578","title":"ZINC FINGER- AND BTB DOMAIN-CONTAINING PROTEIN 1; ZBTB1","url":"https://www.omim.org/entry/616578"}],"hpa":{"profiled":true,"resolved_as":"","reliability":"Supported","locations":[{"location":"Nucleoplasm","reliability":"Supported"},{"location":"Nuclear membrane","reliability":"Additional"}],"tissue_specificity":"Low tissue specificity","tissue_distribution":"Detected in all","driving_tissues":[],"url":"https://www.proteinatlas.org/search/ZBTB1"},"hgnc":{"alias_symbol":["KIAA0997","ZNF909"],"prev_symbol":[]},"alphafold":{"accession":"Q9Y2K1","domains":[{"cath_id":"3.30.160","chopping":"673-713","consensus_level":"medium","plddt":80.668,"start":673,"end":713}],"viewer_url":"https://alphafold.ebi.ac.uk/entry/Q9Y2K1","model_url":"https://alphafold.ebi.ac.uk/files/AF-Q9Y2K1-F1-model_v6.cif","pae_url":"https://alphafold.ebi.ac.uk/files/AF-Q9Y2K1-F1-predicted_aligned_error_v6.png","plddt_mean":54.16},"mouse_models":{"mgi_url":"https://www.informatics.jax.org/marker/summary?nomen=ZBTB1","jax_strain_url":"https://www.jax.org/strain/search?query=ZBTB1"},"sequence":{"accession":"Q9Y2K1","fasta_url":"https://rest.uniprot.org/uniprotkb/Q9Y2K1.fasta","uniprot_url":"https://www.uniprot.org/uniprotkb/Q9Y2K1/entry","alphafold_viewer_url":"https://alphafold.ebi.ac.uk/entry/Q9Y2K1"}},"corpus_meta":[{"pmid":"32268116","id":"PMC_32268116","title":"ZBTB1 Regulates Asparagine Synthesis and Leukemia Cell Response to L-Asparaginase.","date":"2020","source":"Cell metabolism","url":"https://pubmed.ncbi.nlm.nih.gov/32268116","citation_count":63,"is_preprint":false},{"pmid":"24657165","id":"PMC_24657165","title":"Transcriptional repressor ZBTB1 promotes chromatin remodeling and translesion DNA synthesis.","date":"2014","source":"Molecular cell","url":"https://pubmed.ncbi.nlm.nih.gov/24657165","citation_count":53,"is_preprint":false},{"pmid":"22201126","id":"PMC_22201126","title":"ZBTB1 is a determinant of lymphoid development.","date":"2011","source":"The Journal of experimental medicine","url":"https://pubmed.ncbi.nlm.nih.gov/22201126","citation_count":39,"is_preprint":false},{"pmid":"32690611","id":"PMC_32690611","title":"A novel tumor suppressor ZBTB1 regulates tamoxifen resistance and aerobic glycolysis through suppressing HER2 expression in breast cancer.","date":"2020","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/32690611","citation_count":22,"is_preprint":false},{"pmid":"27402700","id":"PMC_27402700","title":"Zbtb1 Safeguards Genome Integrity and Prevents p53-Mediated Apoptosis in Proliferating Lymphoid Progenitors.","date":"2016","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/27402700","citation_count":16,"is_preprint":false},{"pmid":"21706167","id":"PMC_21706167","title":"Novel human BTB/POZ domain-containing zinc finger protein ZBTB1 inhibits transcriptional activities of CRE.","date":"2011","source":"Molecular and cellular biochemistry","url":"https://pubmed.ncbi.nlm.nih.gov/21706167","citation_count":15,"is_preprint":false},{"pmid":"28915559","id":"PMC_28915559","title":"Zbtb1 controls NKp46+ ROR-gamma-T+ innate lymphoid cell (ILC3) development.","date":"2017","source":"Oncotarget","url":"https://pubmed.ncbi.nlm.nih.gov/28915559","citation_count":8,"is_preprint":false},{"pmid":"27542215","id":"PMC_27542215","title":"Zbtb1 prevents default myeloid differentiation of lymphoid-primed multipotent progenitors.","date":"2016","source":"Oncotarget","url":"https://pubmed.ncbi.nlm.nih.gov/27542215","citation_count":8,"is_preprint":false},{"pmid":"38026174","id":"PMC_38026174","title":"RBFOX2 regulated EYA3 isoforms partner with SIX4 or ZBTB1 to control transcription during myogenesis.","date":"2023","source":"iScience","url":"https://pubmed.ncbi.nlm.nih.gov/38026174","citation_count":7,"is_preprint":false},{"pmid":"35394175","id":"PMC_35394175","title":"Circ_0000442 functions as a tumor repressor in breast cancer by impacting miR-1229-3p and upregulating ZBTB1.","date":"2022","source":"Mammalian genome : official journal of the International Mammalian Genome Society","url":"https://pubmed.ncbi.nlm.nih.gov/35394175","citation_count":5,"is_preprint":false},{"pmid":"36126774","id":"PMC_36126774","title":"Transcription factor Zbtb1 interacts with bridging factor Lmo2 and maintains the T-lineage differentiation capacity of lymphoid progenitor cells.","date":"2022","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/36126774","citation_count":4,"is_preprint":false},{"pmid":"34290994","id":"PMC_34290994","title":"MicroRNA and circRNA Expression Analysis in a Zbtb1 Gene Knockout Monoclonal EL4 Cell Line.","date":"2021","source":"Frontiers in cellular and infection microbiology","url":"https://pubmed.ncbi.nlm.nih.gov/34290994","citation_count":3,"is_preprint":false},{"pmid":"35547816","id":"PMC_35547816","title":"Effects of the Zbtb1 Gene on Chromatin Spatial Structure and Lymphatic Development: Combined Analysis of Hi-C, ATAC-Seq and RNA-Seq.","date":"2022","source":"Frontiers in cell and developmental biology","url":"https://pubmed.ncbi.nlm.nih.gov/35547816","citation_count":1,"is_preprint":false},{"pmid":"34956935","id":"PMC_34956935","title":"Analysis of lncRNAs and mRNA Expression in the ZBTB1 Knockout Monoclonal EL4 Cell Line and Combined Analysis With miRNAs and circRNAs.","date":"2021","source":"Frontiers in cellular and infection microbiology","url":"https://pubmed.ncbi.nlm.nih.gov/34956935","citation_count":0,"is_preprint":false},{"pmid":null,"id":"bio_10.1101_2024.06.06.597775","title":"An epigenetically distinct HSC subset supports thymic reconstitution","date":"2024-06-09","source":"bioRxiv","url":"https://doi.org/10.1101/2024.06.06.597775","citation_count":0,"is_preprint":true}],"cost":{"stage1":{"model":"claude-sonnet-4-6","input_tokens":8146,"output_tokens":2748,"usd":0.032829},"stage2":{"model":"claude-opus-4-6","input_tokens":6099,"output_tokens":2733,"usd":0.14823},"total_usd":0.181059,"stage1_batch_id":"msgbatch_01BparvgRZ9S2LMidvaoo86K","stage2_batch_id":"msgbatch_01NkBfv9SVZWthhS7j6mU6G3","note":"batch pricing = 50% of standard"},"stage1_raw":"```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 2014,\n      \"finding\": \"ZBTB1, via its UBZ4 domain, acts as a critical upstream regulator of translesion DNA synthesis (TLS) by associating with KAP-1 and promoting phospho-KAP-1 localization to UV damage sites, which relaxes chromatin and enhances RAD18 recruitment, thereby enabling PCNA monoubiquitination and TLS polymerase recruitment.\",\n      \"method\": \"Co-immunoprecipitation, domain mutagenesis (UBZ4), siRNA depletion, immunofluorescence at UV damage sites, UV survival assays\",\n      \"journal\": \"Molecular cell\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — reciprocal Co-IP, domain mutagenesis, multiple orthogonal functional readouts in a single study\",\n      \"pmids\": [\"24657165\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2011,\n      \"finding\": \"ZBTB1 is localized to the nucleus (dot-like structures) and functions as a transcriptional repressor of CRE-mediated transcription, with both the BTB/POZ domain and zinc finger motifs required for suppression of cAMP response element activity.\",\n      \"method\": \"Subcellular localization by fluorescence microscopy, luciferase transcriptional activity assays, domain deletion analysis in COS7 cells\",\n      \"journal\": \"Molecular and cellular biochemistry\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — direct localization and functional transcription assays; single lab, moderate methods\",\n      \"pmids\": [\"21706167\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2011,\n      \"finding\": \"ZBTB1 is a cell-intrinsic determinant of T cell development and lymphopoiesis; a point mutation in Zbtb1 identified by positional cloning and confirmed by retroviral transduction/somatic reversion causes complete T cell deficiency and partial impairment of other lymphoid lineages.\",\n      \"method\": \"ENU mutagenesis screen, positional cloning, retroviral transduction rescue, somatic reversion analysis in mouse\",\n      \"journal\": \"The Journal of experimental medicine\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — genetic epistasis by multiple complementary approaches (cloning, rescue, reversion) in vivo\",\n      \"pmids\": [\"22201126\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"ZBTB1 directly binds the ASNS (asparagine synthetase) promoter and promotes ASNS transcription, making it uniquely essential for asparagine synthesis under asparagine deprivation; ZBTB1 knockout cells cannot synthesize asparagine and are sensitized to L-asparaginase.\",\n      \"method\": \"Functional genomics/CRISPR screens, ChIP (ZBTB1 at ASNS promoter), knockout cell lines, L-asparaginase survival assays\",\n      \"journal\": \"Cell metabolism\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — genome-wide screen, ChIP validation, KO with specific metabolic phenotype; replicated in multiple leukemia cell contexts\",\n      \"pmids\": [\"32268116\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"Zbtb1 maintains genome integrity in lymphoid progenitors by enabling efficient S-phase checkpoint activation; Zbtb1-mutant progenitors display increased replication stress-associated DNA damage and p53-mediated apoptosis, which can be rescued by Bcl2 overexpression or p53 deficiency—though a Zbtb1-specific block remains at the DN3 stage independent of apoptosis.\",\n      \"method\": \"Bone marrow chimeras with ScanT mutant mice, γH2AX foci quantification, competitive reconstitution, Bcl2 transgene rescue, p53 knockout epistasis\",\n      \"journal\": \"Journal of immunology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — genetic epistasis with multiple rescue experiments and orthogonal phenotypic readouts\",\n      \"pmids\": [\"27402700\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"Zbtb1 expression in lymphoid-primed multipotent progenitors (LMPPs) prevents default myeloid differentiation; Zbtb1-deficient LMPPs upregulate a myeloid gene signature and generate myeloid cells even under lymphoid-inducing conditions without myeloid cytokines, and this lineage bias is independent of p53/Bcl2.\",\n      \"method\": \"In vitro differentiation assays, gene expression profiling, conditional Zbtb1 deficiency in LMPPs, Bcl2/p53 epistasis\",\n      \"journal\": \"Oncotarget\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — clean KO with defined lineage phenotype and epistasis controls; single lab\",\n      \"pmids\": [\"27542215\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"Zbtb1 is cell-intrinsically required for development of NKp46+ RORγt+ ILC3s; Zbtb1-deficient progenitors fail to generate NKp46+ ILC3s in bone marrow chimeras and co-cultures with OP9-DL1 stroma, and fail to upregulate T-bet and acquire IFN-γ production.\",\n      \"method\": \"Bone marrow chimeras, co-culture with OP9-DL1 stroma, flow cytometry, cytokine production assays in Zbtb1-deficient mice\",\n      \"journal\": \"Oncotarget\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — cell-intrinsic rescue experiment in chimeras plus in vitro co-culture; single lab\",\n      \"pmids\": [\"28915559\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"ZBTB1 occupies the ERα-binding site of the HER2 intron and suppresses tamoxifen-induced HER2 transcription in tamoxifen-resistant breast cancer cells; miR-23b-3p directly targets ZBTB1 to relieve this repression, thereby increasing HER2 expression and aerobic glycolysis.\",\n      \"method\": \"ChIP for ZBTB1 at HER2 regulatory sequences, luciferase reporter for miR-23b-3p targeting, ZBTB1 overexpression/knockdown, in vivo xenograft\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — ChIP plus reporter assay plus in vivo validation; single lab\",\n      \"pmids\": [\"32690611\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"Zbtb1 interacts with Lmo2 (identified by two-step affinity purification/LC-MS/MS) and forms a complex with Cbfa2t3; the Lmo2/Zbtb1/Cbfa2t3 complex co-binds the Tcf7 upstream enhancer (shown by ChIP-seq) in lymphoid progenitors, maintaining Tcf7 expression and Notch-mediated T-lineage differentiation capacity.\",\n      \"method\": \"Two-step affinity purification with LC-MS/MS, CRISPR/Cas9 acute disruption, ChIP-seq, transcriptome analysis, Tcf7 retroviral rescue\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 — MS-based interactome, ChIP-seq co-binding, CRISPR KO with specific transcriptional phenotype, and rescue experiment\",\n      \"pmids\": [\"36126774\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"ZBTB1 interacts with EYA3 (identified by mass spectrometry proteomics) and, as a major transcription factor partner, dictates gene expression during myoblast differentiation; EYA3 isoforms differentially regulate this transcriptional partnership.\",\n      \"method\": \"Mass spectrometry-based proteomics, genome-wide transcriptomics (RNA-seq), co-IP/pulldown\",\n      \"journal\": \"iScience\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — MS interactome with transcriptomic follow-up; single lab, moderate functional characterization of the specific ZBTB1–EYA3 interaction\",\n      \"pmids\": [\"38026174\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"Zbtb1 is a lymphoid-specifying transcription factor active in Kit-lo HSCs; deletion of Zbtb1 in Kit-lo HSCs diminishes their T-cell potential, while re-expression in megakaryocytic-biased Kit-hi HSCs rescues T-cell potential in vitro and in vivo.\",\n      \"method\": \"Chromatin profiling (ATAC-seq), CRISPR deletion, retroviral re-expression, in vitro and in vivo T-cell potential assays in allo-HCT mouse model\",\n      \"journal\": \"bioRxiv\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — chromatin profiling plus gain- and loss-of-function in vivo; preprint, not yet peer-reviewed\",\n      \"pmids\": [\"bio_10.1101_2024.06.06.597775\"],\n      \"is_preprint\": true\n    }\n  ],\n  \"current_model\": \"ZBTB1 is a nuclear transcriptional repressor (via its BTB/POZ and C2H2 zinc finger domains) that operates in at least three distinct mechanistic contexts: (1) it binds the ASNS promoter to drive asparagine synthetase transcription under amino acid stress; (2) its UBZ4 domain recruits phospho-KAP-1 to UV-damaged chromatin, enabling RAD18 access, PCNA monoubiquitination, and translesion synthesis; and (3) as part of a Lmo2/Zbtb1/Cbfa2t3 complex, it co-occupies the Tcf7 enhancer to maintain Notch-responsive T-lineage differentiation capacity in lymphoid progenitors.\"\n}\n```","stage2_raw":"```json\n{\n  \"mechanistic_narrative\": \"ZBTB1 is a nuclear BTB/POZ- and C2H2-zinc-finger-containing transcription factor that operates at the intersection of lineage commitment, metabolic adaptation, and genome maintenance. In hematopoietic progenitors, ZBTB1 forms a complex with LMO2 and CBFA2T3 to co-occupy the Tcf7 enhancer, sustaining Notch-responsive T-lineage differentiation capacity; its loss causes complete T-cell deficiency, impaired ILC3 development, and default myeloid differentiation of lymphoid-primed progenitors [PMID:22201126, PMID:36126774, PMID:28915559, PMID:27542215]. ZBTB1 directly binds the ASNS promoter to drive asparagine synthetase transcription under amino acid stress, rendering ZBTB1-null cells unable to synthesize asparagine and hypersensitive to L-asparaginase [PMID:32268116]. Independent of its transcriptional roles, ZBTB1 uses a UBZ4 domain to recruit phospho-KAP-1 to UV-damaged chromatin, relaxing local chromatin structure so that RAD18 can access PCNA for monoubiquitination and translesion synthesis [PMID:24657165].\",\n  \"teleology\": [\n    {\n      \"year\": 2011,\n      \"claim\": \"Establishing that ZBTB1 is a nuclear transcriptional repressor revealed its basic molecular identity — it localizes to nuclear dot-like structures and represses CRE-mediated transcription through both its BTB/POZ domain and zinc finger motifs.\",\n      \"evidence\": \"Fluorescence microscopy and luciferase reporter assays with domain deletions in COS7 cells\",\n      \"pmids\": [\"21706167\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Endogenous genomic targets were not identified\", \"Mechanism of repression (co-repressor recruitment, histone modification) unknown\", \"No assessment in primary cell types\"]\n    },\n    {\n      \"year\": 2011,\n      \"claim\": \"Positional cloning of a T-cell-deficient ENU mutant mouse and retroviral rescue demonstrated that ZBTB1 is a cell-intrinsic determinant of T lymphopoiesis, establishing its first in vivo function.\",\n      \"evidence\": \"ENU mutagenesis screen, positional cloning, retroviral transduction rescue, somatic reversion in mouse\",\n      \"pmids\": [\"22201126\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Direct transcriptional targets in T-cell progenitors were not identified\", \"Mechanism by which the point mutation disrupts ZBTB1 function was unclear\"]\n    },\n    {\n      \"year\": 2014,\n      \"claim\": \"Discovery of a non-transcriptional role resolved how ZBTB1 contributes to genome integrity: its UBZ4 domain recruits phospho-KAP-1 to UV-damaged chromatin, relaxing chromatin to allow RAD18-dependent PCNA monoubiquitination and translesion synthesis.\",\n      \"evidence\": \"Reciprocal Co-IP, UBZ4 domain mutagenesis, siRNA depletion, immunofluorescence at UV damage sites, UV survival assays\",\n      \"pmids\": [\"24657165\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether the UBZ4 domain directly binds ubiquitin or a ubiquitinated substrate was not resolved\", \"Relevance of this pathway to the lymphoid phenotype was not tested\"]\n    },\n    {\n      \"year\": 2016,\n      \"claim\": \"Epistasis experiments clarified that Zbtb1 protects lymphoid progenitors from replication-stress-induced DNA damage and p53-dependent apoptosis, yet a p53-independent block at DN3 revealed an additional lineage-specification role beyond survival.\",\n      \"evidence\": \"γH2AX quantification, Bcl2 transgene rescue, p53 knockout epistasis in bone marrow chimeras of ScanT mutant mice\",\n      \"pmids\": [\"27402700\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Identity of the replication-stress target(s) was not determined\", \"Molecular basis of the p53-independent DN3 block remained open\"]\n    },\n    {\n      \"year\": 2016,\n      \"claim\": \"Demonstrating that Zbtb1-deficient LMPPs default to myeloid fate even under lymphoid-inducing conditions established ZBTB1 as a gatekeeper of lymphoid versus myeloid lineage choice upstream of survival control.\",\n      \"evidence\": \"In vitro differentiation assays with gene expression profiling and Bcl2/p53 epistasis in Zbtb1-deficient LMPPs\",\n      \"pmids\": [\"27542215\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Direct myeloid gene targets repressed by ZBTB1 were not identified\", \"Single-lab finding without independent replication\"]\n    },\n    {\n      \"year\": 2017,\n      \"claim\": \"Extension of the lymphoid requirement to innate lymphoid cells showed that Zbtb1 is cell-intrinsically required for NKp46+ RORγt+ ILC3 development and T-bet-dependent IFN-γ acquisition.\",\n      \"evidence\": \"Bone marrow chimeras and OP9-DL1 co-culture with flow cytometry in Zbtb1-deficient mice\",\n      \"pmids\": [\"28915559\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Direct transcriptional targets in ILC3 progenitors not mapped\", \"Single-lab study\"]\n    },\n    {\n      \"year\": 2020,\n      \"claim\": \"Genome-wide CRISPR screens and ChIP revealed that ZBTB1 directly binds the ASNS promoter to drive asparagine synthetase transcription, establishing a metabolic vulnerability: ZBTB1-null leukemia cells cannot synthesize asparagine and are hypersensitive to L-asparaginase.\",\n      \"evidence\": \"CRISPR screens in multiple leukemia cell lines, ChIP at ASNS promoter, knockout metabolic and survival assays\",\n      \"pmids\": [\"32268116\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether ZBTB1 acts as an activator or relieves a repressor at ASNS was mechanistically unresolved\", \"Relevance to non-leukemic contexts not established\"]\n    },\n    {\n      \"year\": 2020,\n      \"claim\": \"ChIP showed ZBTB1 occupies the ERα-binding site in the HER2 intron and suppresses HER2 transcription, linking ZBTB1 to tamoxifen resistance in breast cancer through a miR-23b-3p/ZBTB1/HER2 regulatory axis.\",\n      \"evidence\": \"ChIP at HER2 regulatory sequences, luciferase reporter, ZBTB1 overexpression/knockdown, xenograft model\",\n      \"pmids\": [\"32690611\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Mechanism of ZBTB1-mediated repression at HER2 locus not defined\", \"Single-lab study\"]\n    },\n    {\n      \"year\": 2022,\n      \"claim\": \"Identification of a LMO2/ZBTB1/CBFA2T3 complex co-occupying the Tcf7 enhancer provided the first molecular mechanism for ZBTB1's T-lineage specification role — maintaining Tcf7 expression and Notch responsiveness in lymphoid progenitors.\",\n      \"evidence\": \"Two-step affinity purification/LC-MS/MS, ChIP-seq co-binding, CRISPR KO, retroviral Tcf7 rescue\",\n      \"pmids\": [\"36126774\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether the complex acts as an activator or prevents silencing was not distinguished\", \"Structural basis of the ternary complex unknown\"]\n    },\n    {\n      \"year\": 2023,\n      \"claim\": \"Proteomic identification of ZBTB1–EYA3 interaction expanded ZBTB1's partnership repertoire to myoblast differentiation, showing it partners with the phosphatase/transactivator EYA3 to regulate differentiation-associated gene expression.\",\n      \"evidence\": \"Mass spectrometry-based proteomics, RNA-seq, co-IP in myoblast differentiation system\",\n      \"pmids\": [\"38026174\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Direct genomic co-occupancy of ZBTB1 and EYA3 not demonstrated\", \"Functional significance of EYA3 isoform-specific effects on ZBTB1 activity not resolved\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"How ZBTB1's transcriptional and chromatin-remodeling functions are coordinated across its distinct biological roles — T-lineage commitment, metabolic stress response, DNA damage tolerance, and potentially myogenesis — remains an open question, as does whether its activating versus repressing activities are context-determined by distinct partner complexes.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"No structural model of full-length ZBTB1 or its complexes exists\", \"Genome-wide binding profile in primary hematopoietic progenitors is incomplete\", \"Relationship between UBZ4-mediated DNA damage function and transcriptional roles is untested\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0140110\", \"supporting_discovery_ids\": [1, 3, 7, 8]},\n      {\"term_id\": \"GO:0003677\", \"supporting_discovery_ids\": [3, 7, 8]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005634\", \"supporting_discovery_ids\": [1]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-73894\", \"supporting_discovery_ids\": [0, 4]},\n      {\"term_id\": \"R-HSA-74160\", \"supporting_discovery_ids\": [1, 3, 7, 8]},\n      {\"term_id\": \"R-HSA-1266738\", \"supporting_discovery_ids\": [2, 5, 6, 8]},\n      {\"term_id\": \"R-HSA-168256\", \"supporting_discovery_ids\": [2, 5, 6]}\n    ],\n    \"complexes\": [\n      \"LMO2/ZBTB1/CBFA2T3\"\n    ],\n    \"partners\": [\n      \"KAP1\",\n      \"LMO2\",\n      \"CBFA2T3\",\n      \"RAD18\",\n      \"EYA3\"\n    ],\n    \"other_free_text\": []\n  }\n}\n```"}